|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2003-4-23
|
|
pubmed:abstractText |
Bosentan, a dual endothelin-receptor antagonist, is registered for the treatment of pulmonary arterial hypertension. Little is known about the effects of bosentan in children. This study was conducted to investigate the pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0009-9236
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
73
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
372-82
|
|
pubmed:dateRevised |
2011-6-2
|
|
pubmed:meshHeading |
pubmed-meshheading:12709727-Adolescent,
pubmed-meshheading:12709727-Analysis of Variance,
pubmed-meshheading:12709727-Antihypertensive Agents,
pubmed-meshheading:12709727-Body Weight,
pubmed-meshheading:12709727-Child,
pubmed-meshheading:12709727-Child, Preschool,
pubmed-meshheading:12709727-Drug Administration Schedule,
pubmed-meshheading:12709727-Female,
pubmed-meshheading:12709727-Half-Life,
pubmed-meshheading:12709727-Hemodynamics,
pubmed-meshheading:12709727-Humans,
pubmed-meshheading:12709727-Hypertension, Pulmonary,
pubmed-meshheading:12709727-Male,
pubmed-meshheading:12709727-Sulfonamides
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension.
|
|
pubmed:affiliation |
Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Gewerbestrasse, Allscwil, Switzerland. paul.cangiersbergen@actelion.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
